Fast Five Quiz: Rheumatoid Arthritis Management

Herbert S. Diamond, MD; Abhishek Nandan, MD


February 22, 2023

A recent randomized controlled trial concluded that triple therapy was superior to MTX monotherapy in preventing relapse among patients with RA. This approach has also been deemed to be more cost-effective than TNF inhibitor maintenance therapy and MTX monotherapy.

A recent real-world study, however, concluded that drug persistence and clinical effectiveness outcomes were less favorable in triple-therapy patients compared with TNF inhibitor/MTX-therapy patients. Another study comparing the real-world effectiveness of biologic therapy (a biologic DMARD plus MTX) vs triple therapy concluded that biologic therapy was more effective for remaining on therapy and achieving sustained remission. Biologic therapy was also shown to be more effective in sustaining remission in a nationwide register study. However, for certain patients with RA, triple therapy may still represent a viable alternative to biologic therapy.

Learn more about combination therapies with csDMARDs.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.